The stock of Vir Biotechnology Inc (VIR) has gone down by -28.77% for the week, with a -7.86% drop in the past month and a -20.20% drop in the past quarter. The volatility ratio for the week is 8.50%, and the volatility levels for the past 30 days are 6.95% for VIR. The simple moving average for the past 20 days is -17.29% for VIR’s stock, with a -23.52% simple moving average for the past 200 days.
Is It Worth Investing in Vir Biotechnology Inc (NASDAQ: VIR) Right Now?
Moreover, the 36-month beta value for VIR is 0.49. Analysts have varying opinions on the stock, with 5 analysts rating it as a “buy,” 4 as “overweight,” 3 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for VIR is 87.38M and currently, short sellers hold a 6.55% of that float. On November 19, 2024, VIR’s average trading volume was 923.07K shares.
VIR) stock’s latest price update
The stock of Vir Biotechnology Inc (NASDAQ: VIR) has decreased by -12.23 when compared to last closing price of 8.01. Despite this, the company has experienced a -28.77% fall in its stock price over the last five trading sessions. businesswire.com reported 2024-11-18 that SAN FRANCISCO–(BUSINESS WIRE)–Vir Biotechnology, Inc. (NASDAQ:VIR) today announced positive results from the SOLSTICE Phase 2 clinical trial evaluating tobevibart alone, or in combination with elebsiran, in people with chronic hepatitis delta (CHD). The most-advanced and potential first-of-its-kind investigational human monoclonal antibody and siRNA combination dosed monthly achieved 100% virologic response and rapid hepatitis delta virus (HDV) RNA suppression. HDV RNA below the lower limit o.
Analysts’ Opinion of VIR
Many brokerage firms have already submitted their reports for VIR stocks, with JP Morgan repeating the rating for VIR by listing it as a “Neutral.” The predicted price for VIR in the upcoming period, according to JP Morgan is $9 based on the research report published on January 29, 2024 of the current year 2024.
BofA Securities, on the other hand, stated in their research note that they expect to see VIR reach a price target of $14, previously predicting the price at $23. The rating they have provided for VIR stocks is “Neutral” according to the report published on September 08th, 2023.
JP Morgan gave a rating of “Overweight” to VIR, setting the target price at $34 in the report published on March 06th of the previous year.
VIR Trading at -11.99% from the 50-Day Moving Average
After a stumble in the market that brought VIR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -46.29% of loss for the given period.
Volatility was left at 6.95%, however, over the last 30 days, the volatility rate increased by 8.50%, as shares sank -8.10% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -10.10% lower at present.
During the last 5 trading sessions, VIR fell by -28.77%, which changed the moving average for the period of 200-days by -18.92% in comparison to the 20-day moving average, which settled at $8.50. In addition, Vir Biotechnology Inc saw -30.12% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VIR starting from de Verneuil Vanina, who sale 4,397 shares at the price of $10.11 back on Nov 06 ’24. After this action, de Verneuil Vanina now owns 56,973 shares of Vir Biotechnology Inc, valued at $44,454 using the latest closing price.
VANINA DE VERNEUIL, the Officer of Vir Biotechnology Inc, proposed sale 4,397 shares at $9.64 during a trade that took place back on Nov 06 ’24, which means that VANINA DE VERNEUIL is holding shares at $42,387 based on the most recent closing price.
Stock Fundamentals for VIR
Current profitability levels for the company are sitting at:
- -6.58 for the present operating margin
- 0.82 for the gross margin
The net margin for Vir Biotechnology Inc stands at -6.78. The total capital return value is set at -0.37. Equity return is now at value -36.58, with -30.10 for asset returns.
Based on Vir Biotechnology Inc (VIR), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -5.0. The debt to equity ratio resting at 0.08. The interest coverage ratio of the stock is -2165.5.
Currently, EBITDA for the company is -664.85 million with net debt to EBITDA at 0.1. When we switch over and look at the enterprise to sales, we see a ratio of 11.61. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.94.
Conclusion
To wrap up, the performance of Vir Biotechnology Inc (VIR) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
